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ABSTRACT 428 
Body fat distribution is a heritable risk factor for a range of adverse health consequences, 429 
including hyperlipidemia and type 2 diabetes. To identify protein-coding variants associated with body 430 
fat distribution, assessed by waist-to-hip ratio adjusted for body mass index, we analyzed 246,328 431 
predicted coding and splice site variants available on exome arrays in up to 344,369 individuals from five 432 
major ancestries for discovery and 132,177 independent European-ancestry individuals for validation. 433 
We identified 15 common (minor allele frequency, MAF ≥ 5%) and 9 low frequency or rare (MAF < 5%) 434 
coding variants that have not been reported previously. Pathway/gene set enrichment analyses of all 435 
associated variants highlight lipid particle, adiponectin level, abnormal white adipose tissue physiology, 436 
and bone development and morphology as processes affecting fat distribution and body shape. 437 
Furthermore, the cross-trait associations and the analyses of variant and gene function highlight a 438 
strong connection to lipids, cardiovascular traits, and type 2 diabetes. In functional follow-up analyses, 439 
specifically in Drosophila RNAi-knockdown crosses, we observed a significant increase in the total body 440 
triglyceride levels for two genes (DNAH10 and PLXND1). By examining variants often poorly tagged or 441 
entirely missed by genome-wide association studies, we implicate novel genes in fat distribution, 442 
stressing the importance of interrogating low-frequency and protein-coding variants. 443 
 444 
 445 
 446 
 447 
 448 
449 
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Body fat distribution, as assessed by waist-to-hip ratio (WHR), is a heritable trait and a well-450 
established risk factor for adverse metabolic outcomes1-6. A high WHR often indicates a large presence 451 
of intra-abdominal fat whereas a low WHR is correlated with a greater accumulation of gluteofemoral 452 
fat. Lower values of WHR have been consistently associated with lower risk of cardiometabolic diseases 453 
like type 2 diabetes (T2D)7,8, or differences in bone structure and gluteal muscle mass9. These 454 
epidemiological associations are consistent with the results of our previously reported genome-wide 455 
association study (GWAS) of 49 loci associated with WHR (after adjusting for body mass index, 456 
WHRadjBMI)10. Notably, a genetic predisposition to higher WHRadjBMI is associated with increased risk 457 
of T2D and coronary heart disease (CHD), and this association appears to be causal9. 458 
More recently, large-scale genetic studies have identified ~125 common loci for central obesity, 459 
primarily non-coding variants of relatively modest effect, for different measures of body fat 460 
distribution10-16. Large scale interrogation of both common (minor allele frequency [MAF]≥5%) and low 461 
frequency or rare (MAF<5%) coding and splice site variation may lead to additional insights into the 462 
genetic and biological etiology of central obesity by narrowing in on causal genes contributing to trait 463 
variance. Thus, we set out to identify protein-coding and splice site variants associated with WHRadjBMI 464 
using exome array data and to explore their contribution to variation in WHRadjBMI through multiple 465 
follow-up analyses. 466 
RESULTS 467 
Protein-coding and splice site variation associated with body fat distribution 468 
We conducted a 2-stage fixed-effects meta-analysis testing both additive and recessive models 469 
in order to detect protein-coding genetic variants that influence WHRadjBMI (Online Methods, Figure 470 
1). Our stage 1 meta-analysis included up to 246,328 variants (218,195 with MAF<5%) from up to 471 
344,369 individuals from 74 studies of European (N=288,492), South Asian (N=29,315), African 472 
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(N=15,687), East Asian (N=6,800) and Hispanic/Latino (N=4,075) descent, genotyped with an ExomeChip 473 
array (Supplementary Tables 1-3). For stage 2, we assessed 70 suggestively significant (P<2x10-6) 474 
variants from stage 1 (Online Methods, Supplementary Data 1-3) in two independent cohorts from the 475 
United Kingdom [UK Biobank (UKBB), N=119,572] and Iceland (deCODE, N=12,605) (Online Methods, 476 
Supplementary Data 1-3) for a total stage 1+2 sample size of 476,546 (88% European). Variants were 477 
considered statistically significant in the total meta-analyzed sample (stage 1+2) when they achieved a 478 
significance threshold of P<2x10-7 after Bonferroni correction for multiple testing (0.05/246,328 variants 479 
tested), and considered novel if they were greater than one megabase (Mb) from a previously-identified 480 
WHRadjBMI lead SNP10-16.  481 
In stages 1 and 2 combined all ancestry meta-analyses, we identified 48 coding variants (16 482 
novel) across 43 genes, 47 identified assuming an additive model, and one more variant under a 483 
recessive model (Table 1). Due to the possible heterogeneity introduced by combining multiple 484 
ancestries17, we also performed a European-only meta-analysis. Here, four additional coding variants 485 
were significant (three novel) assuming an additive model. Of these 52 significant variants (48 from the 486 
all ancestry and 4 from the European-only analyses), eleven were of low frequency, including seven 487 
novel variants in RAPGEF3, FGFR2, R3HDML, HIST1H1T, PCNXL3, ACVR1C, and DARS2 (Table 1, 488 
Supplementary Figures 1-7). These low frequency variants tended to display larger effect estimates than 489 
any of the previously reported common variants (Figure 2)10. In general, variants with MAF<1% had 490 
effect sizes approximately three times greater than those of common variants (MAF>5%). There are 491 
likely additional rare variants with smaller effects sizes that we are underpowered to detect. However, 492 
in the absence of common variants with similarly large effects, our results point to the importance of 493 
investigating rare and low frequency variants to identify variants with large effects (Figure 2).  494 
Given the established differences in the genetic underpinnings between sexes for 495 
WHRadjBMI10,11, we also performed sex-stratified analyses and report variants that were array-wide 496 
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significant (P<2x10-7) in at least one sex stratum and exhibit significant sex-specific effects 497 
(Psexhet<7.14x10-4, see Online Methods). We found four additional novel variants that were not identified 498 
in the sex-combined meta-analyses (in UGGT2 and MMP14 for men only; and DSTYK and ANGPTL4 for 499 
women only) (Table 2, Supplementary Figures 7-11). Variants in UGGT2 and ANGPTL4 were of low 500 
frequency (MAFmen=0.6% and MAFwomen=1.9%, respectively). Additionally, 14 variants from the sex-501 
combined meta-analyses displayed stronger effects in women, including the novel, low frequency 502 
variant in ACVR1C (rs55920843, MAF=1.1%). Overall, 19 of the 56 variants (32%) identified across all 503 
meta-analyses (48 from all ancestry, 4 from European-only and 4 from sex-stratified analyses) showed 504 
significant sex-specific effects on WHRadjBMI (Figure 1): 16 variants with significantly stronger effects in 505 
women, and three in men (Figure 1).  506 
In summary, we identified 56 array-wide significant coding variants (P<2.0x10-7); 43 common (14 507 
novel) and 13 low frequency or rare variants (9 novel). For all 55 significant variants from the additive 508 
model only (47 from all ancestry, 4 from European-only, and 4 from sex-specific analyses), we examined 509 
potential collider bias, i.e. potential bias in effect estimates caused by adjusting for a correlated and 510 
heritable covariate like BMI, for the relevant sex stratum and ancestry (Online Methods, Supplementary 511 
Table 7, Supplementary Note 1). Overall, 38 of the 55 variants were robust against collider bias18,19 512 
across all primary and secondary meta-analyses (P<2x10-7 following correction), and an additional three 513 
variants were robust against collider bias in the women-only analysis but not in the sex-combined. The 514 
effect estimates of the remaining 14 variants (Supplementary Table 7, Supplementary Note 1) did not 515 
remain array-wide significant following correction. Thus, these 14 variants warrant further functional 516 
investigations to quantify their impact on WHR, as a true association may still exist, although the effect 517 
may be slightly overestimated in the current analysis. 518 
Using stage 1 meta-analysis results, we then aggregated low frequency variants across genes 519 
and tested their joint effect with both SKAT and burden tests20 (Supplementary Table 8, Online 520 
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Methods). We identified five genes that reached array-wide significance (P<2.5x10-6, 0.05/16,222 genes 521 
tested), RAPGEF3, ACVR1C, ANGPTL4, DNAI1, and NOP2. However, while all genes analyzed included 522 
more than one variant, none remained significant after conditioning on the single variant with the most 523 
significant p-value, suggesting these associations are driven by a single variant. 524 
 525 
Conditional analyses 526 
 We next implemented conditional analyses to determine (1) the number of independent 527 
association signals the 56 array-wide significant coding (23 novel) variants represent, and (2) whether 528 
the 33 variants near known GWAS association signals (<+/- 1Mb) represented independent novel 529 
association signals. To determine if these variants were independent association signals, we used 530 
approximate joint conditional analyses to test for independence in stage 1 (Online Methods; 531 
Supplementary Table 4)20. Only the RSPO3-KIAA0408 locus contains two independent variants 291 Kb 532 
apart, rs1892172 in RSPO3 (MAF=46.1%, Pconditional=4.37x10-23 in the combined sexes, and 533 
Pconditional=2.4x10-20 in women) and rs139745911 in KIAA0408 (MAF=0.9%, Pconditional=3.68x10-11 in the 534 
combined sexes, and Pconditional=1.46x10-11 in women; Figure 3).  535 
Further, 33 of our significant variants are within one Mb of previously identified GWAS tag SNPs 536 
for WHRadjBMI. We again used approximate joint conditional analysis to test for independence in the 537 
stage 1 meta-analysis dataset and obtained further complementary evidence from the UKBB dataset 538 
where necessary (Online Methods). We identified one coding variant representing a novel independent 539 
signal in a known locus [RREB1; stage1 meta-analysis, rs1334576, EAF = 0.44, Pconditional= 3.06x10-7, 540 
(Supplementary Table 5, Figure 3 [B]); UKBB analysis, rs1334576, RREB1, Pconditional= 1.24x10-8, 541 
(Supplementary Table 6) in the sex-combined analysis.  542 
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In summary, we identified a total of 56 WHRadjBMI-associated coding variants in 41 543 
independent association signals. Of these 41 independent association signals, 24 are new or 544 
independent of known GWAS-identified tag SNPs (either >1MB +/- or array-wide significant following 545 
conditional analyses) (Figure 1). The remaining non-GWAS-independent variants may assist in narrowing 546 
in on the causal variant or gene underlying these established association signals. 547 
Gene set and pathway enrichment analysis 548 
To determine if the significant coding variants highlight novel biological pathways and/or 549 
provide additional support for previously identified biological pathways, we applied two complementary 550 
pathway analysis methods using the EC-DEPICT (ExomeChip Data-driven Expression Prioritized 551 
Integration for Complex Traits) pathway analysis tool,21,22 and PASCAL23 (Online Methods). We examined 552 
361 variants with suggestive significance (P<5x10-4)10,17 from the combined ancestries and combined 553 
sexes analysis, as well as variants that exhibited significant sex-specific effects (Psexhet<5x10-4).  554 
The sex-combined analyses identified 49 significantly enriched gene sets (FDR<0.05) that 555 
grouped into 25 meta-gene sets (Supplementary Note 2, Supplementary Data 4-5). We noted a cluster 556 
of meta-gene sets with direct relevance to metabolic aspects of obesity (“enhanced lipolysis,” 557 
“abnormal glucose homeostasis,” “increased circulating insulin level,” and “decreased susceptibility to 558 
diet-induced obesity”). While these pathway groups had previously been identified in the GWAS DEPICT 559 
analysis (Figure 4), many of the individual gene sets within these meta-gene sets were not significant in 560 
the previous GWAS analysis, such as “insulin resistance,” “abnormal white adipose tissue physiology,” 561 
and “abnormal fat cell morphology” (Supplementary Data 4, Figure 4, Supplementary Figure 12a), but 562 
represent similar biological underpinnings implied by the shared meta-gene sets. These analyses 563 
highlight novel genes that fall outside known GWAS loci, based on their strong contribution to the 564 
significantly enriched gene sets related to adipocyte and insulin biology (Figure 4).  565 
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To focus on novel findings, we conducted pathway analyses after excluding variants from 566 
previous WHRadjBMI analyses10 (Supplemental Note 2). Seventy-five loci/genes were included in the 567 
DEPICT analysis, and we identified 26 significantly enriched gene sets (13 meta-gene sets). Here, all but 568 
one gene set, “lipid particle size”, were related to skeletal biology. This result likely reflects an effect on 569 
the pelvic skeleton (hip circumference), shared signaling pathways between bone and fat (such as TGF-570 
beta) and shared developmental origin24 (Supplementary Data 5, Supplementary Figure 12b).  571 
We used PASCAL (Online Methods) to further distinguish between enrichment based on coding-572 
only variant associations (this study) and regulatory-only variant associations (up to 20 kb upstream of 573 
the gene from a previous GIANT study10). For completeness, we also compared the coding pathways to 574 
those that could be identified in the total previous GWAS effort (using both coding and regulatory 575 
variants) by PASCAL. The analysis revealed 109 significantly enriched coding pathways (FDR<0.05; 576 
Supplementary Table 9). A total of 111 gene sets were identified only in the coding+regulatory analysis 577 
that included ExomeChip data. Thus, while we observed high concordance in the -log10 (p-values) 578 
between ExomeChip and GWAS gene set enrichment (Pearson's r (coding vs regulatory only) = 0.38, 579 
P<10-300; Pearson's r (coding vs coding+regulatory) = 0.51, P<10-300), there are gene sets that seem to be 580 
enriched specifically for variants in coding regions (e.g., decreased susceptibility to diet-induced obesity, 581 
abnormal skeletal morphology) or unique to variants in regulatory regions (e.g. transcriptional 582 
regulation of white adipocytes) (Supplementary Figure 13).  583 
Cross-trait associations 584 
To assess the relevance of our identified variants with cardiometabolic (lipids, diabetes-related, 585 
blood pressure), anthropometric (height and BMI), and reproductive traits (age at menopause and 586 
menarche), we conducted association lookups from existing ExomeChip studies of 15 traits 587 
(Supplementary Data 6, Supplementary Figure 14). We found that variants in STAB1 and PLCB3 display 588 
the greatest number of significant cross-trait associations, each with seven different traits (P<9.8x10-4, 589 
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0.05/51 variants tested). Of note, these two genes cluster together with RSPO3, DNAH10, MNS1, 590 
COBLL1, CCDC92, and ITIH3. The WHR-increasing allele in this cluster of variants exhibit a pattern of 591 
increased cardiometabolic risk (e.g. increased fasting insulin [FI], two-hour glucose [TwoHGlu], and 592 
triglycerides [TG]; and decreased high-density lipoprotein cholesterol [HDL]), but also decreased BMI 593 
(Supplementary Data 6, Supplementary Figure 14). Among the traits we examined, height (19 variants), 594 
HDL (18 variants), and BMI (16 variants) have the greatest number of significant associations with 595 
WHRadjBMI-associated ExomeChip variants. Many of our novel variants exhibit significant associations 596 
with lipid-related traits, including variants in DAGLB (HDL), MGA (HDL, TG), RASIP1 (low-density 597 
lipoprotein cholesterol [LDL], TG, total cholesterol [TC]), and IZUMO1 (LDL, TG, TC). Further, significant 598 
cross-trait associations are consistent with expected direction of effect for several traits, i.e. the WHR-599 
increasing allele is associated with higher values of TG, DBP, fasting insulin, TC , LDL and T2D when 600 
compared to the WHR across all significant variants (P<9.8x10-4). The WHR-increasing allele decreases 601 
HDL for 89% of significantly associated variants (Supplementary Data 6, Supplementary Figure 14).  602 
Given the established correlation between total body fat percentage and WHR (R= 0.052 to 603 
0.483)25-27, we examined the association of our top exome variants with both total body fat percentage 604 
and truncal fat percentage available in a sub-sample of up to 118,160 participants of UKBB 605 
(Supplementary Tables 10-11). Seven of the common novel variants were significantly associated 606 
(P<0.001, 0.05/48 variants examined) with both total body and truncal fat percentage in the sexes-607 
combined analysis (COBLL1, UHRF1BP1, WSCD2, CCDC92, IFI30, MPV17L2, IZUMO1). Only one of our tag 608 
SNPs, rs7607980 in COBLL1, is nearby a known total body fat percentage GWAS locus (rs6738627; 609 
R2=0.1989, distance=6751 bp, with our tag SNP)28. Two additional variants, rs62266958 in EFCAB12 and 610 
rs224331 in GDF5, were significantly associated with truncal fat in the women-only analysis. Of the nine 611 
SNPs associated with at least one of these two traits, all variants displayed much greater magnitude of 612 
effect on truncal fat compared to total body fat (Supplementary Figure 15).  613 
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Previous studies have demonstrated the importance of examining common and rare variants 614 
within genes with mutations known to cause monogenic diseases29,30. We assessed enrichment of our 615 
WHRadjBMI within genes that cause monogenic forms of lipodystrophy) and/or insulin resistance 616 
(Supplementary Data 7). No significant enrichment was observed (Supplementary Figure 16). For 617 
lipodystrophy, the lack of significant findings may be due in part to the small number of implicated 618 
genes and the relatively small number of variants in monogenic disease causing genes, reflecting their 619 
intolerance of variation.  620 
Genetic architecture of WHRadjBMI coding variants 621 
We used summary statistics from our stage 1 results to estimate the phenotypic variance 622 
explained by ExomeChip coding variants. We calculated the variance explained by subsets of SNPs across 623 
various significance thresholds (P< 2x10-7 to 0.2) and conservatively estimated using only independent 624 
tag SNPs (Supplementary Table 12, Online Methods, and Supplementary Figure 17). The 22 625 
independent significant coding SNPs in stage 1 account for 0.28% of phenotypic variance in WHRadjBMI. 626 
For independent variants that reached suggestive significance in stage 1 (P<2x10-6), 33 SNPs explain 627 
0.38% of the variation; however, the 1,786 independent SNPs with a liberal threshold of P<0.02 explain 628 
13 times more variation (5.12%). While these large effect estimates may be subject to winner’s curse, 629 
for array-wide significant variants, we detected a consistent relationship between effect magnitude and 630 
MAF in our stage 2 analyses in UK Biobank and deCODE (Supplementary Data 1-3). Notably, the 631 
Exomechip coding variants explained less of the phenotypic variance than in our previous GIANT 632 
investigation, wherein 49 significant SNPs explained 1.4% of the variance in WHRadjBMI. When 633 
considering all coding variants on the ExomeChip in men and women together, 46 SNPs with a P<2x10-6 634 
and 5,917 SNPs with a P<0.02 explain 0.51% and 13.75% of the variance in WHRadjBMI, respectively. As 635 
expected given the design of the ExomeChip, the majority of the variance explained is attributable to 636 
rare and low frequency coding variants (independent SNPs with MAF<1% and MAF<5% explain 5.18% 637 
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and 5.58%, respectively). However, for rare and low frequency variants, those that passed significance in 638 
stage 1 explain only 0.10% of the variance in WHRadjBMI. As in Figure 2, these results also indicate that 639 
there are additional coding variants associated with WHRadjBMI that remain to be discovered, 640 
particularly rare and low frequency variants with larger effects than common variants. Due to observed 641 
differences in association strength between women and men, we estimated variance explained for the 642 
same set of SNPs in women and men separately. As observed in previous studies10, there was 643 
significantly (PRsqDiff<0.002=0.05/21, Bonferroni-corrected threshold) more variance explained in women 644 
compared to men at each significance threshold considered (differences ranged from 0.24% to 0.91%).  645 
To better understand the potential clinical impact of WHRadjBMI associated variants, we 646 
conducted penetrance analysis using the UKBB population (both sexes combined, and men- and women-647 
only). We compared the number of carriers and non-carriers of the minor allele for each of our 648 
significant variants in centrally obese and non-obese individuals to determine if there is a significant 649 
accumulation of the minor allele in either the centrally obese or non-obese groups (Online Methods). 650 
Three rare and low frequency variants (MAF ≤ 1%) with larger effect sizes (effect size > 0.90) were 651 
included in the penetrance analysis using World Health Organization (WHO- obese women WHR>0.85 652 
and obese men WHR>0.90) WHR cut-offs for central obesity. Of these, one SNV (rs55920843-ACVR1C; 653 
Psex-combined=9.25x10-5; Pwomen=4.85x10-5) showed a statistically significant difference in the number of 654 
carriers and non-carriers of the minor allele when the two strata were compared (sex-combined obese 655 
carriers=2.2%; non-obese carriers=2.6%; women obese carriers=2.1%; non-obese women carriers=2.6% 656 
(Supplementary Table 13, Supplementary Figure 18). These differences were significant in women, but 657 
not in men (Pmen<5.5x10-3 after Bonferroni correction for 9 tests) and agree with our overall meta-658 
analysis results, where the minor allele (G) was significantly associated with higher WHRadjBMI in 659 
women only (Tables 1 and 2). 660 
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Evidence for functional role of significant variants 661 
Drosophila Knockdown 662 
Considering the genetic evidence of adipose and insulin biology in determining body fat 663 
distribution10, and the lipid signature of the variants described here, we examined whole-body 664 
triglycerides levels in adult Drosophila, a model organism in which the fat body is an organ functionally 665 
analogous to mammalian liver and adipose tissue and triglycerides are the major source of fat storage31. 666 
Of the 51 genes harboring our 56 significantly associated variants, we identified 27 with Drosophila 667 
orthologues for functional follow-up analyses. In order to prioritize genes for follow-up, we selected 668 
genes with large changes in triglyceride storage levels (> 20% increase or > 40% decrease, as chance 669 
alone is unlikely to cause changes of this magnitude, although some decrease is expected) after 670 
considering each corresponding orthologue in an existing large-scale screen for adipose with ≤2 671 
replicates per knockdown strain.31 Two orthologues, for PLXND1 and DNAH10, from two separate loci 672 
met these criteria. For these two genes, we conducted additional knockdown experiments with ≥5 673 
replicates using tissue-specific drivers (fat body [cg-Gal4] and neuronal [elav-Gal4] specific RNAi-674 
knockdowns) (Supplementary Table 14). A significant (P<0.025, 0.05/2 orthologues) increase in the total 675 
body triglyceride levels was observed in DNAH10 orthologue knockdown strains for both the fat body 676 
and neuronal drivers. However, only the neuronal driver knockdown for PLXND1 produced a significant 677 
change in triglyceride storage. DNAH10 and PLXND1 both lie within previous GWAS identified regions 678 
(Box 1). Adjacent genes have been highlighted as likely candidates for the DNAH10 association region, 679 
including CCDC92 and ZNF664 based on eQTL evidence. However, our fly knockdown results support 680 
DNAH10 as the causal genes underlying this association. Of note, rs11057353 in DNAH10 showed 681 
suggestive significance after conditioning on the known GWAS variants in nearby CCDC92 (sex-combined 682 
Pconditional=7.56x10-7; women-only rs11057353 Pconditional= 5.86x10-7, Supplementary Table 6; thus 683 
providing some evidence of multiple causal variants/genes underlying this association signal. Further 684 
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analyses are needed to determine whether the implicated coding variants from the current analysis are 685 
the putatively functional variants. 686 
eQTL Lookups  687 
To gain a better understanding of the potential functionality of novel and low frequency 688 
variants, we examined the cis-association of the identified variants with expression level of nearby genes 689 
in subcutaneous adipose tissue, visceral omental adipose tissue, skeletal muscle and pancreas from 690 
GTEx32, and assessed whether the exome and eQTL associations implicated the same signal (Online 691 
Methods, Supplementary Data 8-9, Supplementary Table 15). The lead exome variant was associated 692 
with expression level of the coding gene itself for DAGLB, MLXIPL, CCDC92, MAPKBP1, LRRC36 and 693 
UQCC1. However, at three of these loci (MLXIPL, MAPKBP1, and LRRC36), the lead exome variant is also 694 
associated with expression level of additional nearby genes, and at three additional loci, the lead exome 695 
variant is only associated with expression level of nearby genes (HEMK1 at C3orf18; NT5DC2, SMIM4 696 
and TMEM110 at STAB1/ITIH3; and C6orf106 at UHRF1BP1). Although detected with a missense variant, 697 
these loci are also consistent with a regulatory mechanism of effect as they are significantly associated 698 
with expression levels of genes, and the association signal may well be due to LD with nearby regulatory 699 
variants.  700 
Some of the coding genes implicated by eQTL analyses are known to be involved in adipocyte 701 
differentiation or insulin sensitivity: e. g. for MLXIPL, the encoded carbohydrate responsive element 702 
binding protein is a transcription factor, regulating glucose-mediated induction of de novo lipogenesis in 703 
adipose tissue, and expression of its beta-isoform in adipose tissue is positively correlated with adipose 704 
insulin sensitivity33,34. For CCDC92, the reduced adipocyte lipid accumulation upon knockdown 705 
confirmed the involvement of its encoded protein in adipose differentiation35.  706 
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Biological Curation 707 
To gain further insight into the possible functional role of the identified variants, we conducted 708 
thorough searches of the literature and publicly available bioinformatics databases (Supplementary 709 
Data 9-10, Box 1, Online Method). Many of our novel low frequency variants are in genes that are 710 
intolerant of nonsynonymous mutations (e.g. ACVR1C, DARS2, FGFR2; ExAC Constraint Scores >0.5). Like 711 
previously identified GWAS variants, several of our novel coding variants lie within genes that are 712 
involved in glucose homeostasis (e.g. ACVR1C, UGGT2, ANGPTL4), angiogenesis (RASIP1), adipogenesis 713 
(RAPGEF3), and lipid biology (ANGPTL4, DAGLB) (Supplementary Data 9, Box 1).  714 
 715 
DISCUSSION  716 
Our two-staged approach to analysis of coding variants from ExomeChip data in up to 476,546 717 
individuals identified a total of 56 array-wide significant variants in 41 independent association signals, 718 
including 24 newly identified (23 novel and one independent of known GWAS signals) that influence 719 
WHRadjBMI. Nine of these variants were low frequency or rare, indicating an important role for low 720 
frequency variants in the polygenic architecture of fat distribution and providing further insights into its 721 
underlying etiology. While, due to their rarity, these coding variants only explain a small proportion of 722 
the trait variance at a population level, they may, given their predicted role, be more functionally 723 
tractable than non-coding variants and have a critical impact at the individual and clinical level. For 724 
instance, the association between a low frequency variant (rs11209026; R381Q; MAF<5% in ExAC) 725 
located in the IL23R gene encoding a subunit of the interleukin 23 (IL23) receptor and multiple 726 
inflammatory diseases (such as psoriasis36, rheumatoid arthritis37, ankylosing spondylitis38, and 727 
inflammatory bowel diseases39) led to the development of new therapies, targeting IL23 and IL12 in the 728 
same pathway (reviewed in 40-42). Although a large proportion of variance at the population level still 729 
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needs to be accounted for in these inflammatory diseases, the contribution of this association to 730 
understanding disease mechanisms and the development of new therapies has been tremendous 731 
(reviewed in 41,42). Thus, we are encouraged that our associated low frequency coding variants displayed 732 
large effect sizes; all but one of the nine novel low frequency variants had an effect size larger than the 733 
49 SNPs reported in Shungin et al. 2015, and some of these effect sizes were up to 7-fold larger than 734 
those previously reported for GWAS. This finding mirrors results for other cardiometabolic traits43, and 735 
suggests variants of possible clinical significance with even larger effect and lower frequency variants 736 
will likely be detected through larger additional genome-wide scans of many more individuals. 737 
We continue to observe sexual dimorphism in the genetic architecture of WHRadjBMI11. Overall, 738 
we identified 19 coding variants that display significant sex differences, of which 16 (84%) display larger 739 
effects in women compared to men. Of the variants outside of GWAS loci, we reported three (two with 740 
MAF<5%) that show a significantly stronger effect in women and two (one with MAF<5%) that show a 741 
stronger effect in men. Additionally, genetic variants continue to explain a higher proportion of the 742 
phenotypic variation in body fat distribution in women compared to men10,11. Of the novel female 743 
(DSTYK and ANGPTL4) and male (UGGT2 and MMP14) specific signals, only ANGPTL4 implicated fat 744 
distribution related biology associated with both lipid biology and cardiovascular traits (Box 1). Sexual 745 
dimorphism in fat distribution is apparent from childhood and throughout adult life44-46, and at sexually 746 
dimorphic loci, hormones with different levels in men and women may interact with genomic and 747 
epigenomic factors to regulate gene activity, though this remains to be experimentally documented. 748 
Dissecting the underlying molecular mechanisms of the sexual dimorphism in body fat distribution, and 749 
also how it is correlated with – and causing – important comorbidities like T2D and cardiovascular 750 
diseases will be crucial for improved understanding of disease risk and pathogenesis. 751 
Overall, we observe fewer significant associations between WHRadjBMI and coding variants on 752 
the ExomeChip than Turcot et al. (In press) examining the association of low frequency and rare coding 753 
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variants with BMI. In line with these observations, we identify fewer pathways and cross-trait 754 
associations. One reason for fewer WHRadjBMI implicated variants and pathways may be smaller 755 
sample size (NWHRadjBMI = 476,546, NBMI = 718,639), and thus, lower statistical power. Power, however, is 756 
likely not the only contributing factor. For example, Turcot et al. (In Press) have comparative sample 757 
sizes between BMI and that of Marouli et al.22 studying height (Nheight = 711,428). However, greater than 758 
seven times the number of coding variants are identified for height than for BMI, indicating that perhaps 759 
a number of other factors, including trait architecture, heritability (possibly overestimated in some 760 
phenotypes), and phenotype precision, likely all contribute to our study’s capacity to identify low 761 
frequency and rare variants with large effects. Further, it is possible that the comparative lack of 762 
significant findings for WHRadjBMI and BMI compared to height may be a result of higher selective 763 
pressure against genetic predisposition to cardiometabolic phenotypes, such as BMI and WHR. As 764 
evolutionary theory predicts that harmful alleles will be low frequency47, we may need larger sample 765 
sizes to detect rare variants that have so far escaped selective pressures. Lastly, the ExomeChip is 766 
limited by the variants that are present on the chip, which was largely dictated by sequencing studies in 767 
European-ancestry populations and a MAF detection criteria of ~0.012%. It is likely that though an 768 
increased sample size, use of chips designed to detect variation across a range of continental ancestries, 769 
and/or alternative study designs, future studies will detect additional variation from the entire allele 770 
frequency spectrum that contributes to fat distribution phenotypes. 771 
The collected genetic and epidemiologic evidence has now demonstrated that fat distribution 772 
(as measured by increased WHRadjBMI) is correlated with increased risk of T2D and CVD, and that this 773 
association is likely causal with potential mediation through blood pressure, triglyceride-rich 774 
lipoproteins, glucose, and insulin9. This observation yields an immediate follow-up question: Which 775 
mechanisms regulate depot-specific fat accumulation and are risks for disease, driven by increased 776 
visceral or decreased subcutaneous adipose tissue mass (or both)? Pathway analysis identified several 777 
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novel pathways and gene sets related to metabolism and adipose regulation, bone growth and 778 
development. Similarly, expression/eQTL results support the function and relevance of adipogenesis, 779 
adipocyte biology, and insulin signaling, supporting our previous findings for WHRadjBMI10. We also 780 
provide evidence suggesting known biological functions and pathways contributing to body fat 781 
distribution (e.g., diet-induced obesity, angiogenesis, bone growth and morphology, and enhanced 782 
lipolysis). 783 
A seminal finding from this study is the importance of lipid metabolism for body fat distribution. 784 
In fact, pathway analyses that highlight enhanced lipolysis, cross-trait associations with circulating lipid 785 
levels, existing biological evidence from the literature, and knockdown experiments in Drosophila 786 
examining triglyceride storage point to novel candidate genes (ANGPTL4, ACVR1C, DAGLB, MGA, RASIP1, 787 
and IZUMO1) and new candidates in known regions (DNAH1010 and MLXIPL14) related to lipid biology 788 
and its role in fat storage. Newly implicated genes of interest include ACVR1C, MLXIPL, and ANGPTL4, all 789 
of which are involved in lipid homeostasis; all are excellent candidate genes for central adiposity. 790 
Carriers of inactivating mutations in ANGPTL4 (Angiopoietin Like 4), for example, display low triglyceride 791 
levels and low risk of coronary artery disease48. ACVR1C encodes the activin receptor-like kinase 7 792 
protein (ALK7), a receptor for the transcription factor TGFB-1, well known for its central role in growth 793 
and development in general49-53, and adipocyte development in particular53. ACVR1C exhibits the highest 794 
expression in adipose tissue, but is also highly expressed in the brain54-56. In mice, decreased activity of 795 
ACVR1C upregulates PPARγ and C/EBPα pathways and increases lipolysis in adipocytes, thus decreasing 796 
weight and diabetes in mice54,57,58. Such activity is suggestive of a role for ALK7 in adipose tissue 797 
signaling and therefore for therapeutic targets for human obesity. MLXIPL, also important for lipid 798 
metabolism and postnatal cellular growth, is a transcription factor which activates triglyceride synthesis 799 
genes in a glucose-dependent manner59,60. The lead exome variant in this gene is highly conserved, most 800 
likely damaging, and is associated with reduced MLXIPL expression in adipose tissue. Furthermore, in a 801 
  
  35 
recent longitudinal, in vitro transcriptome analysis of adipogenesis in human adipose-derived stromal 802 
cells, gene expression of MLXIPL was up-regulated during the maturation of adipocytes, suggesting a 803 
critical role in the regulation of adipocyte size and accumulation61.  804 
Taken together, our 24 novel variants for WHRadjBMI offer new biology, highlighting the 805 
importance of lipid metabolism in the genetic underpinnings of body fat distribution. We continue to 806 
demonstrate the critical role of adipocyte biology and insulin resistance for central obesity and offer 807 
support for potentially causal genes underlying previously identified fat distribution GWAS loci. Notably, 808 
our findings offer potential new therapeutic targets for intervention in the risks associated with 809 
abdominal fat accumulation, and represents a major advance in our understanding of the underlying 810 
biology and genetic architecture of central adiposity. 811 
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Overseeing of contributing studies: (1958 Birth Cohort) PD; (Airwave) PE; (AMC PAS) GKH; (Amish) 984 
JRO'C; (ARIC) EB; (ARIC, Add Health) KEN; (BRAVE) EDA, RC; (BRIGHT) PBM; (CARDIA) MF, PJS; (Cebu 985 
Longitudinal Health and Nutrition Survey) KLM; (CHD Exome + Consortium) ASB, JMMH, DFR, JD; (CHES) 986 
RV; (Clear/eMERGE (Seattle)) GPJ; (CROATIA_Korcula) VV, OP, IR; (deCODE) KS, UT; (DHS) DWB; 987 
(DIACORE) CAB; (DPS) JT, JL, MU; (DRSEXTRA) TAL, RR; (EFSOCH) ATH, TMF; (EGCUT) TE; (eMERGE 988 
(Seattle)) EBL; (EPIC-Potsdam) MBS, HB; (EpiHealth) EI, PWF; (EXTEND) ATH, TMF; (Family Heart Study) 989 
IBB; (Fenland, EPIC) RAS; (Fenland, EPIC, InterAct) NJW, CL; (FINRISK) SM; (FINRISK 2007 (T2D) ) PJ, VS; 990 
(Framingham Heart Study) LAC; (FUSION) MB, FSC; (FVG) PG; (Generation Scotland) CH, BHS; (Genetic 991 
Epidemiology Network of Arteriopathy (GENOA)) SLRK; (GRAPHIC) NJS; (GSK-STABILITY) DMW, LW, 992 
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HDW; (Health) AL; (HELIC MANOLIS) EZ, GD; (HELIC Pomak) EZ, GD; (HUNT-MI) KH, CJW; (Inter99) TH, TJ; 993 
(IRASFS) LEW, EKS; (Jackson Heart Study (JHS)) JGW; (KORA S4) KS, IMH; (Leipzig-Adults) MB, PK; 994 
(LOLIPOP-Exome) JCC, JSK; (LOLIPOP-OmniEE) JCC, JSK; (MESA) JIR, XG; (METSIM) JK, ML; (MONICA-995 
Brianza) GC; (Montreal Heart Institute Biobank (MHIBB)) MPD, GL, SdD, JCT; (MORGAM Central 996 
Laboratory) MP; (MORGAM Data Centre) KK; (OBB) FK; (PCOS) APM, CML; (PIVUS) CML, LL; (PRIME - 997 
Belfast) FK; (PRIME - Lille) PA; (PRIME - Strasbourg) MM; (PRIME - Toulouse) JF; (PROMIS) DS; (QC) MAR; 998 
(RISC) BB, EF, MW; (Rotterdam Study I) AGU, MAI; (SEARCH) AMD; (SHIP/SHIP-Trend) MD; (SIBS) DFE; 999 
(SOLID TIMI-52) DMW; (SORBS) APM, MS, AT; (The Mount Sinai BioMe Biobank) EPB, RJFL; (The NEO 1000 
Study) DOMK; (The NHAPC study, The GBTDS study) XL; (The Western Australian Pregnancy Cohort 1001 
(Raine) Study) CEP, SM; (TwinsUK) TDS; (ULSAM) APM; (Vejle Biobank) IB, CC, OP; (WGHS) DIC, PMR; 1002 
(Women's Health Initiative) PLA; (WTCCC-UKT2D) MIM, KRO; (YFS) TL, OTRa; Genotyping of contributing 1003 
studies: (1958 Birth Cohort) KES; (Airwave) EE, MPSL; (AMC PAS) SS; (Amish) LMYA, JAP; (ARIC) EWD, 1004 
MG; (BBMRI-NL) SHV, LB, CMvD, PIWdB; (BRAVE) EDA; (Cambridge Cancer Studies) JGD; (CARDIA) MF; 1005 
(CHD Exome + Consortium) ASB, JMMH, DFR, JD, RY(Clear/eMERGE (Seattle)) GPJ; (CROATIA_Korcula) 1006 
VV; (DIACORE) CAB, MG; (DPS) AUJ, JL; (DRSEXTRA) PK; (EGCUT) TE; (EPIC-Potsdam) MBS, KM; 1007 
(EpiHealth) EI, PWF; (Family Heart Study) KDT; (Fenland, EPIC) RAS; (Fenland, EPIC, InterAct) NJW, CL; 1008 
(FUSION) NN; (FVG) IG, AM; (Generation Scotland) CH; (Genetic Epidemiology Network of Arteriopathy 1009 
(GENOA)) SLRK, JAS; (GRAPHIC) NJS; (GSK-STABILITY) DMW; (Health) JBJ; (HELIC MANOLIS) LS; (HELIC 1010 
Pomak) LS; (Inter99) TH, NG; (KORA) MMN; (KORA S4) KS, HG; (Leipzig-Adults) AM; (LOLIPOP-Exome) 1011 
JCC, JSK; (LOLIPOP-OmniEE) JCC, JSK; (MESA) JIR, YDIC, KDT; (METSIM) JK, ML; (Montreal Heart Institute 1012 
Biobank (MHIBB)) MPD; (OBB) FK; (PCOS) APM; (PIVUS) CML; (Rotterdam Study I) AGU, CMG, FR; (SDC) 1013 
JMJ, HV; (SEARCH) AlMD; (SOLID TIMI-52) DMW; (SORBS) APM; (The Mount Sinai BioMe Biobank) EPB, 1014 
RJFL, YL, CS; (The NEO Study) RLG; (The NHAPC study, The GBTDS study) XL, HL, YH; (The Western 1015 
Australian Pregnancy Cohort (Raine) Study) CEP, SM; (TUDR) ZA; (TwinsUK) APM; (ULSAM) APM; (WGHS) 1016 
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DIC, AYC; (Women's Health Initiative) APR; (WTCCC-UKT2D) MIM; (YFS) TL, LPL; Phenotyping of 1017 
contributing studies: (Airwave) EE; (AMC PAS) SS; (Amish) LM YA; (ARIC) EWD; (ARIC, Add Health) KEN; 1018 
(BBMRI-NL) SHV; (BRAVE) EDA; (BRIGHT) MJC; (CARL) AR, GG; (Cebu Longitudinal Health and Nutrition 1019 
Survey) NRL; (CHES) RV, MT; (Clear/eMERGE (Seattle)) GPJ, AAB; (CROATIA_Korcula) OP, IR; (DIACORE) 1020 
CAB, BKK; (DPS) AUJ, JL; (EFSOCH) ATH; (EGCUT) EM; (EPIC-Potsdam) HB; (EpiHealth) EI; (EXTEND) ATH; 1021 
(Family Heart Study) MFF; (Fenland, EPIC, InterAct) NJW; (FIN-D2D 2007) LM, MV; (FINRISK) SM; 1022 
(FINRISK 2007 (T2D)) PJ, HS; (Framingham Heart Study) CSF; (Generation Scotland) CH, BHS; (Genetic 1023 
Epidemiology Network of Arteriopathy (GENOA)) SLRK, JAS; (GRAPHIC) NJS; (GSK-STABILITY) LW, HDW; 1024 
(Health) AL, BHT; (HELIC MANOLIS) LS, AEF, ET; (HELIC Pomak) LS, AEF, MK; (HUNT-MI) KH, OH; (Inter99) 1025 
TJ, NG; (IRASFS) LEW, BK; (KORA) MMN; (LASA (BBMRI-NL)) KMAS; (Leipzig-Adults) MB, PK; (LOLIPOP-1026 
Exome) JCC, JSK; (LOLIPOP-OmniEE) JCC, JSK; (MESA) MA; (Montreal Heart Institute Biobank (MHIBB)) 1027 
GL, KSL, VT; (MORGAM Data Centre) KK; (OBB) FK, MN; (PCOS) CML; (PIVUS) LL; (PRIME - Belfast) FK; 1028 
(PRIME - Lille) PA; (PRIME - Strasbourg) MM; (PRIME - Toulouse) JF; (RISC) BB, EF; (Rotterdam Study I) 1029 
MAI, CMGFR, MCZ; (SHIP/SHIP-Trend) NF; (SORBS) MS, AT; (The Mount Sinai BioMe Biobank) EPB, YL, 1030 
CS; (The NEO Study) RdM; (The NHAPC study, The GBTDS study) XL, HL, LS, FW; (The Western Australian 1031 
Pregnancy Cohort (Raine) Study) CEP; (TUDR) YJH, WJL; (TwinsUK) TDS, KSS; (ULSAM) VG; (WGHS) DIC, 1032 
PMR; (Women's Health Initiative) APR; (WTCCC-UKT2D) MIM, KRO; (YFS) TL, OTR; Data analysis of 1033 
contributing studies: (1958 Birth Cohort) KES, IN; (Airwave) EE, MPSL; (AMC PAS) SS; (Amish) JRO'C, 1034 
LMYA, JAP; (ARIC, Add Health) KEN, KLY, MG; (BBMRI-NL) LB; (BRAVE) RC, DSA; (BRIGHT) HRW; 1035 
(Cambridge Cancer Studies) JGD, AP, DJT; (CARDIA) MF, LAL; (CARL) AR, DV; (Cebu Longitudinal Health 1036 
and Nutrition Survey) YW; (CHD Exome + Consortium) ASB, JMMH, DFR, RY, PS; (CHES) YJ; 1037 
(CROATIA_Korcula) VV; (deCODE) VS, GT; (DHS) AJC, PM, MCYN; (DIACORE) CAB, MG; (EFSOCH) HY; 1038 
(EGCUT) TE, RM; (eMERGE (Seattle)) DSC; (ENDO) TK; (EPIC) JHZ; (EPIC-Potsdam) KM; (EpiHealth) SG; 1039 
(EXTEND) HY; (Family Heart Study) MFF; (Fenland) JaL; (Fenland, EPIC) RAS; (Fenland, InterAct) SMW; 1040 
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(Finrisk Extremes and QC) SV; (Framingham Heart Study) CTL, NLHC; (FVG) IG; (Generation Scotland) CH, 1041 
JM; (Genetic Epidemiology Network of Arteriopathy (GENOA)) LFB; (GIANT-Analyst) AEJ; (GRAPHIC) NJS, 1042 
NGDM, CPN; (GSK-STABILITY) DMW, AS; (Health) JBJ; (HELIC MANOLIS) LS; (HELIC Pomak) LS; (HUNT-MI) 1043 
WZ; (Inter99) NG; (IRASFS) BK; (Jackson Heart Study (JHS)) LAL, JL; (KORA S4) TWW; (LASA (BBMRI-NL)) 1044 
KMAS; (Leipzig-Adults) AM; (LOLIPOP-Exome) JCC, JSK, WZ; (LOLIPOP-OmniEE) JCC, JSK, WZ; (MESA) JIR, 1045 
XG, JY; (METSIM) XS; (Montreal Heart Institute Biobank (MHIBB)) JCT, GL, KSL, VT; (OBB) AM; (PCOS) 1046 
APM, TK; (PIVUS) NR; (PROMIS) AR, WZ; (QC GoT2D/T2D-GENES (FUSION, METSIM, etc)) AEL; (RISC) HY; 1047 
(Rotterdam Study I) CMG, FR; (SHIP/SHIP-Trend) AT; (SOLID TIMI-52) DMW, AS; (SORBS) APM; (The 1048 
Mount Sinai BioMe Biobank) YL, CS; (The NEO Study) RLG; (The NHAPC study, The GBTDS study) XL, HL, 1049 
YH; (The Western Australian Pregnancy Cohort (Raine) Study) CAW; (UK Biobank) ARW; (ULSAM) APM, 1050 
AM; (WGHS) DIC, AYC; (Women's Health Initiative) PLA, JH; (WTCCC-UKT2D) WG; (YFS) LPL. 1051 
 1052 
METHODS  1053 
Studies 1054 
Stage 1 consisted of 74 studies (12 case/control studies, 59 population-based studies, and five 1055 
family studies) comprising 344,369 adult individuals of the following ancestries: 1) European descent (N= 1056 
288,492), 2) African (N= 15,687), 3) South Asian (N= 29,315), 4) East Asian (N=6,800), and 5) Hispanic 1057 
(N=4,075). Stage 1 meta-analyses were carried out in each ancestry separately and in the all ancestries 1058 
group, for both sex-combined and sex-specific analyses. Follow-up analyses were undertaken in 132,177 1059 
individuals of European ancestry from the deCODE anthropometric study and UK Biobank 1060 
(Supplementary Tables 1-3). Conditional analyses were performed in the all ancestries and European 1061 
descent groups. 1062 
Phenotypes 1063 
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For each study, WHR (waist circumference divided by hip circumference) was corrected for age, 1064 
BMI, and the genomic principal components (derived from GWAS data, the variants with MAF >1% on 1065 
the ExomeChip, and ancestry informative markers available on the ExomeChip), as well as any additional 1066 
study-specific covariates (e.g. recruiting center), in a linear regression model. For studies with non-1067 
related individuals, residuals were calculated separately by sex, whereas for family-based studies sex 1068 
was included as a covariate in models with both men and women. Additionally, residuals for 1069 
case/control studies were calculated separately. Finally, residuals were inverse normal transformed and 1070 
used as the outcome in association analyses. Phenotype descriptives by study are shown in 1071 
Supplementary Table 3. 1072 
Genotypes and QC 1073 
The majority of studies followed a standardized protocol and performed genotype calling using 1074 
the algorithms indicated in Supplementary Table 2, which typically included zCall3. For 10 studies 1075 
participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 1076 
Consortium, the raw intensity data for the samples from seven genotyping centers were assembled into 1077 
a single project for joint calling4. Study-specific quality control (QC) measures of the genotyped variants 1078 
were implemented before association analysis (Supplementary Tables 1-2).  1079 
Study-level statistical analyses 1080 
Individual cohorts were analyzed for each ancestry separately, in sex-combined and sex-specific 1081 
groups, with either RAREMETALWORKER (http://genome.sph.umich.edu/wiki/RAREMETALWORKER) or 1082 
RVTESTs (http://zhanxw.github.io/rvtests/), to associate inverse normal transformed WHRadjBMI with 1083 
genotype accounting for cryptic relatedness (kinship matrix) in a linear mixed model. These software 1084 
programs are designed to perform score-statistic based rare-variant association analysis, can 1085 
accommodate both unrelated and related individuals, and provide single-variant results and variance-1086 
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covariance matrices. The covariance matrix captures linkage disequilibrium (LD) relationships between 1087 
markers within 1 Mb, which is used for gene-level meta-analyses and conditional analyses62,63. Single-1088 
variant analyses were performed for both additive and recessive models.  1089 
Centralized quality-control 1090 
Individual cohorts identified ancestry population outliers based on 1000 Genome Project phase 1091 
1 ancestry reference populations. A centralized quality-control procedure implemented in EasyQC64 was 1092 
applied to individual cohort association summary statistics to identify cohort-specific problems: (1) 1093 
assessment of possible errors in phenotype residual transformation; (2) comparison of allele frequency 1094 
alignment against 1000 Genomes Project phase 1 reference data to pinpoint any potential strand issues, 1095 
and (3) examination of quantile-quantile (QQ) plots per study to identify any inflation arising from 1096 
population stratification, cryptic relatedness and genotype biases.  1097 
Meta-analyses 1098 
Meta-analyses were carried out in parallel by two different analysts at two sites using 1099 
RAREMETAL62. During the meta-analyses, we excluded variants if they had call rate <95%, Hardy-1100 
Weinberg equilibrium P-value <1x10-7, or large allele frequency deviations from reference populations 1101 
(>0.6 for all ancestries analyses and >0.3 for ancestry-specific population analyses). We also excluded 1102 
from downstream analyses markers not present on the Illumina ExomeChip array 1.0, variants on the Y-1103 
chromosome or the mitochondrial genome, indels, multiallelic variants, and problematic variants based 1104 
on the Blat-based sequence alignment analyses. Significance for single-variant analyses was defined at 1105 
an array-wide level (P<2x10-7). For all suggestive significant variants from Stage 1, we tested for 1106 
significant sex differences. We calculated Psexhet for each SNP, testing for difference between women-1107 
specific and men-specific beta estimates and standard errors using EasyStrata11,65 Each SNP that reached 1108 
Psexhet<0.05/# of variants tested was considered significant. 1109 
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For the gene-based analyses, we applied two sets of criteria to select variants with a MAF<5% 1110 
within each ancestry based on coding variant annotation from five prediction algorithms (PolyPhen2, 1111 
HumDiv and HumVar, LRT, MutationTaster and SIFT)65,66. Our broad gene-based tests included nonsense, 1112 
stop-loss, splice site, and missense variants annotated as damaging by at least one algorithm mentioned 1113 
above. Our strict gene-based tests included only nonsense, stop-loss, splice site, and missense variants 1114 
annotated as damaging by all five algorithms. These analyses were performed using the sequence kernel 1115 
association test (SKAT) and variable threshold (VT) methods. Statistical significance for gene-based tests 1116 
was set at a Bonferroni-corrected threshold of P<2.5x10-6. All gene-based tests were performed in 1117 
RAREMETAL62. 1118 
Genomic inflation 1119 
We observed a marked genomic inflation of the test statistics even after controlling for 1120 
population stratification (linear mixed model) arising mainly from common markers; λGC in the primary 1121 
meta-analysis (combined ancestries and combined sexes) was 1.08 and 1.43 for all and only common 1122 
markers, respectively (Supplementary Figures 4 and 7 and Supplementary Table 16). Such inflation is 1123 
expected for a highly polygenic trait like WHRadjBMI, for studies using a non-random set of variants 1124 
across the genome, and is consistent with our very large sample size64,67,68. 1125 
Conditional analyses 1126 
The RAREMETAL R-package62 was used to identify independent WHRadjBMI association signals 1127 
across all ancestries and European meta-analysis results. RAREMETAL performs conditional analyses by 1128 
using covariance matrices to distinguish true signals from the shadows of adjacent significant variants in 1129 
LD. First, we identified the lead variants (P<2x10-7) based on a 1Mb window centered on the most 1130 
significantly associated variant. We then conditioned on the lead variants in RAREMETAL and kept new 1131 
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lead signals at P<2x10-7 for conditioning in a second round of analysis. The process was repeated until no 1132 
additional signal emerged below the pre-specified P-value threshold (P<2x10-7). 1133 
To test if the associations detected were independent of the previously published WHRadjBMI 1134 
variants 10,14,16, we performed conditional analyses in the stage 1 discovery set if the GWAS variant or its 1135 
proxy (r20.8) was present on the ExomeChip using RAREMETAL62. All variants identified in our meta-1136 
analysis and the previously published variants were also present in the UK Biobank dataset69. This 1137 
dataset was used as a replacement dataset if a good proxy was not present on the ExomeChip as well as 1138 
a replication dataset for the variants present on the ExomeChip. All conditional analyses in the UK 1139 
Biobank dataset were performed using SNPTEST70-72. The conditional analyses were carried out 1140 
reciprocally, conditioning on the exome chip variant and then the previously published variant. An 1141 
association was considered independent of the previously published association if there was a 1142 
statistically significant association detected prior to the conditional analysis (P<2x10-7) with both the 1143 
exome chip variant and the previously published variant, and the observed association with both or 1144 
either of the variants disappeared upon conditional analysis (P>0.05). A conditional p-value between 1145 
9x10-6 and 0.05 was considered inconclusive. However, a conditional p-value < 9x10-6 was also 1146 
considered suggestive. 1147 
 1148 
Stage 2 meta-analyses 1149 
In our Stage 2, we sought to validate a total of 70 variants from Stage 1 that met P<2x10-6 in two 1150 
independent studies, the UK Biobank (Release 169) and Iceland (deCODE), comprising 119,572 and 1151 
12,605 individuals, respectively (Supplementary Tables 1-3). The same QC and analytical methodology 1152 
were used for these studies. Genotyping, study descriptions and phenotype descriptives are provided in 1153 
Supplementary Tables 11, 12 and 13. For the combined analysis of Stage 1 plus 2, we used the inverse-1154 
variance weighted fixed effects meta-analysis method. Significant associations were defined as those 1155 
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nominally significant (P<0.05) in the Stage 2 study and for the combined meta-analysis (Stage 1 plus 1156 
Stage 2) significance was set at P<2x10-7. 1157 
Pathway enrichment analyses: DEPICT 1158 
We adapted DEPICT, a gene set enrichment analysis method for GWAS data, for use with the 1159 
ExomeChip (‘EC-DEPICT’); this method is also described in a companion manuscript22. DEPICT’s primary 1160 
innovation is the use of “reconstituted” gene sets, where many different types of gene sets (e.g. 1161 
canonical pathways, protein-protein interaction networks, and mouse phenotypes) were extended 1162 
through the use of large-scale microarray data (see Pers et al.21 for details). EC-DEPICT computes p-1163 
values based on Swedish ExomeChip data (Malmö Diet and Cancer (MDC), All New Diabetics in Scania 1164 
(ANDIS), and Scania Diabetes Registry (SDR) cohorts, N=11,899) and, unlike DEPICT, takes as input only 1165 
the genes directly containing the significant (coding) variants rather than all genes within a specified 1166 
amount of linkage disequilibrium (see Supplementary Note 2). 1167 
Two analyses were performed for WHRadjBMI ExomeChip: one with all variants p<5x10-4 (49 1168 
significant gene sets in 25 meta-gene sets, FDR <0.05) and one with all variants > 1 Mb from known 1169 
GWAS loci 10 (26 significant gene sets in 13 meta-gene sets, FDR <0.05). Affinity propagation clustering73 1170 
was used to group highly correlated gene sets into “meta-gene sets”; for each meta-gene set, the 1171 
member gene set with the best p-value was used as representative for purposes of visualization (see 1172 
Supplementary Note). DEPICT for ExomeChip was written using the Python programming language, and 1173 
the code can be found at https://github.com/RebeccaFine/obesity-ec-depict. 1174 
Pathway enrichment analyses: PASCAL 1175 
We also applied the PASCAL pathway analysis tool23 to exome-wide association summary 1176 
statistics from Stage 1 for all coding variants. The method derives gene-based scores (both SUM and 1177 
MAX statistics) and subsequently tests for over-representation of high gene scores in predefined 1178 
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biological pathways. We used standard pathway libraries from KEGG, REACTOME and BIOCARTA, and 1179 
also added dichotomized (Z-score>3) reconstituted gene sets from DEPICT21. To accurately estimate 1180 
SNP-by-SNP correlations even for rare variants, we used the UK10K data (TwinsUK74 and ALSPAC75 1181 
studies , N=3781). In order to separate the contribution of regulatory variants from the coding variants, 1182 
we also applied PASCAL to association summary statistics of only regulatory variants (20 kb upstream) 1183 
and regulatory+coding variants from the Shungin et al10 study. In this way, we could comment on what is 1184 
gained by analyzing coding variants available on ExomeChip arrays. We performed both MAX and SUM 1185 
estimations for pathway enrichment. MAX is more sensitive to genesets driven primarily by a single 1186 
signal, while SUM is better when there are multiple variant associations in the same gene.  1187 
Monogenic obesity enrichment analyses 1188 
We compiled two lists consisting of 31 genes with strong evidence that disruption causes 1189 
monogenic forms of insulin resistance or diabetes; and 8 genes with evidence that disruption causes 1190 
monogenic forms of lipodystrophy. To test for enrichment of association, we conducted simulations by 1191 
matching each gene with others based on gene length and number of variants tested, to create a 1192 
matched set of genes. We generated 1,000 matched gene sets from our data, and assessed how often 1193 
the number of variants exceeding set significance thresholds was greater than in our monogenic obesity 1194 
gene set.  1195 
Variance explained 1196 
We estimated the phenotypic variance explained by the association signals in Stage 1 all 1197 
ancestries analyses for men, women, and combined sexes76. For each associated region, we pruned 1198 
subsets of SNPs within 500 kb, as this threshold was comparable with previous studies, of the SNPs with 1199 
the lowest P-value and used varying P value thresholds (ranging from 2x10-7 to 0.02) from the combined 1200 
sexes results. Additionally, we examined all variants and independent variants across a range of MAF 1201 
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thresholds. The variance explained by each subset of SNPs in each strata was estimated by summing the 1202 
variance explained by the individual top coding variants. For the comparison of variance explained 1203 
between men and women, we tested for the significance of the differences assuming that the weighted 1204 
sum of chi-squared distributed variables tend to a Gaussian distribution ensured by Lyapunov’s central 1205 
limit theorem.76,77 1206 
Cross-trait lookups 1207 
To carefully explore the relationship between WHRadjBMI and related cardiometabolic, 1208 
anthropometric, and reproductive traits, association results for the 51 WHRadjBMI coding SNPs were 1209 
requested from existing or on-going meta-analyses from 7 consortia, including ExomeChip data from 1210 
GIANT (BMI, height), Global Lipids Genetics Consortium Results (GLGC) (total cholesterol, triglycerides, 1211 
HDL-cholesterol, LDL-cholesterol), International Consortium for Blood Pressure (IBPC)78 (systolic and 1212 
diastolic blood pressure), Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) 1213 
(glycemic traits), and DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium (type 2 1214 
diabetes). For coronary artery disease, we accessed 1000 Genomes Project-imputed GWAS data 1215 
released by CARDIoGRAMplusC4D79 and for the ReproGen consortium (age at menarche and 1216 
menopause) we used a combination of ExomeChip and 1000 Genomes Project-Imputed GWAS data. 1217 
Heatmaps were generated in R v3.3.2 using gplots (https://CRAN.R-project.org/package=gplots). We 1218 
used Euclidean distance based on p-value and direction of effect and complete linkage clustering for the 1219 
dendrograms. 1220 
Body-fat percentage associations 1221 
We performed body fat percent and truncal fat percent look-up of 48 of the 56 identified 1222 
variants (tables 1 and 2) that were available in the UK Biobank, Release 169, data (notably some of the 1223 
rare variants in table 1 and 2 were not available) to further characterize their effects on WHRadjBMI. 1224 
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Genome-wide association analyses for body fat percent and truncal fat percent were carried out in the 1225 
UK Biobank. Prior to analysis, phenotype data were filtered to exclude pregnant or possibly pregnant 1226 
women, individuals with body mass index < 15, and without genetically confirmed European ancestry, 1227 
resulting in a sample size of 120,286. Estimated measures of body fat percent and truncal fat percent 1228 
were obtained using the Tanita BC418MA body composition analyzer (Tanita, Tokyo, Japan). Individuals 1229 
were not required to fast and did not follow any specific instructions prior to the bioimpedance 1230 
measurements. SNPTEST was used to perform the analyses based on residuals adjusted for age, 15 1231 
principle components, assessment center and the genotyping chip70.  1232 
Collider bias 1233 
In order to evaluate SNPs for possible collider bias, we used results from an ongoing association 1234 
analysis from GIANT on BMI to first identify SNPs with effects in the opposite direction between 1235 
WHRadjBMI and BMI and with P<0.05 for BMI. For each SNP that met these criteria, WHRadjBMI 1236 
associations were adjusted for the correlation between the two traits to obtain new effect estimates 1237 
using the following equations: 1238 
𝛽corrected =  𝛽𝑊𝐻𝑅𝑎𝑑𝑗𝐵𝑀𝐼 +  𝛽𝐵𝑀𝐼  ×  𝜌 1239 
 1240 
,and 1241 
𝑆𝐸𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =  √(𝑆𝐸𝑊𝐻𝑅𝑎𝑑𝑗𝐵𝑀𝐼
2 +  𝜌2  × 𝑆𝐸𝐵𝑀𝐼
2   1242 
 1243 
where 𝜌 is the phenotypic correlation between WHR and BMI (0.49).  1244 
Drosophila RNAi knockdown experiments  1245 
For each gene in which coding variants were associated with WHRadjBMI in the final combined 1246 
meta-analysis (P < 2×10-7), its corresponding Drosophila orthologues were identified in the Ensembl 1247 
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ortholog database (www.ensembl.org), when available. Drosophila triglyceride content values were 1248 
mined from a publicly available genome-wide fat screen data set 31 to identify potential genes for follow-1249 
up knockdowns. Estimated values represent fractional changes in triglyceride content in adult male flies. 1250 
Data are from male progeny resulting from crosses of male UAS-RNAi flies from the Vienna Drosophila 1251 
Resource Center (VDRC) and Hsp70-GAL4; Tub-GAL8ts virgin females. Two-to-five-day-old males were 1252 
sorted into groups of 20 and subjected to two one-hour wet heatshocks four days apart. On the seventh 1253 
day, flies were picked in groups of eight, manually crushed and sonicated, and the lysates heat-1254 
inactivated for 10 min in a thermocycler at 95 °C. Centrifuge-cleared supernatants were then used for 1255 
triglyceride (GPO Trinder, Sigma) and protein (Pierce) determination. Triglyceride values from these 1256 
adult-induced ubiquitous RNAi knockdown individuals were normalized to those obtained in parallel 1257 
from non-heatshocked progeny from the very same crosses. The screen comprised one to three 1258 
biological replicates. We followed up each gene with a >0.2 increase or >0.4 decrease in triglyceride 1259 
content.  1260 
Orthologues for two genes were brought forward for follow-up, DNAH10 and PLXND1. For both 1261 
genes, we generated adipose tissue (cg-Gal4) and neuronal (elav-Gal4) specific RNAi-knockdown crosses, 1262 
leveraging upstream activation sequence (UAS)-inducible short-hairpin knockdown lines, available 1263 
through the VDRC (Vienna Drosophila Resource Center). We crossed male UAS-RNAi flies and elav-GAL4 1264 
or CG-GAL4 virgin female flies. All fly experiments were carried out at 25°C. Five-to-seven-day-old males 1265 
were sorted into groups of 20, weighed and homogenated in PBS with 0.05% Tween with Lysing Matrix 1266 
D in a beadshaker. The homogenate was heat-inactivated for 10 min in a thermocycler at 70°C. 10μl of 1267 
the homogenate was subsequently used in a triglyceride assay (Sigma, Serum Triglyceride Determination 1268 
Kit) which was carried out in duplicate according to protocol, with one alteration: the samples were 1269 
cleared of residual particulate debris by centrifugation before absorbance reading. Resulting triglyceride 1270 
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values were normalized to fly weight and larval/population density. We used the non-parametric 1271 
Kruskall-Wallis test to compare wild type with knockdown lines. 1272 
Expression quantitative trait loci (eQTLs) analysis 1273 
We queried the significant variant (Exome coding SNPs)-gene pairs associated with eGenes 1274 
across five metabolically relevant tissues (skeletal muscle, subcutaneous adipose, visceral adipose, liver 1275 
and pancreas) with at least 70 samples in the GTEx database32. For each tissue, variants were selected 1276 
based on the following thresholds: the minor allele was observed in at least 10 samples, and the minor 1277 
allele frequency was ≥ 0.01. eGenes, genes with a significant eQTL, are defined on a false discovery rate 1278 
(FDR)80 threshold of ≤0.05 of beta distribution-adjusted empirical p-value from FastQTL. Nominal p-1279 
values were generated for each variant-gene pair by testing the alternative hypothesis that the slope of 1280 
a linear regression model between genotype and expression deviates from 0. To identify the list of all 1281 
significant variant-gene pairs associated with eGenes, a genome-wide empirical p-value threshold64, pt, 1282 
was defined as the empirical p-value of the gene closest to the 0.05 FDR threshold. pt was then used to 1283 
calculate a nominal p-value threshold for each gene based on the beta distribution model (from 1284 
FastQTL) of the minimum p-value distribution f(pmin) obtained from the permutations for the gene. For 1285 
each gene, variants with a nominal p-value below the gene-level threshold were considered significant 1286 
and included in the final list of variant-gene pairs64. For each eGene, we also listed the most significantly 1287 
associated variants (eSNP). Only these exome SNPs with r2 > 0.8 with eSNPs were considered for the 1288 
biological interpretation (Supplementary eQTL GTEx). 1289 
We also performed cis-eQTL analysis in 770 METSIM subcutaneous adipose tissue samples as 1290 
described in Civelek, et al.81 A false discovery rate (FDR) was calculated using all p-values from the cis-1291 
eQTL detection in the q-value package in R. Variants associated with nearby genes at an FDR less than 1292 
1% were considered to be significant (equivalent p-value < 2.46 × 10−4).  1293 
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For loci with more than one microarray probeset of the same gene associated with the exome 1294 
variant, we selected the probeset that provided the strongest LD r2 between the exome variant and the 1295 
eSNP. In reciprocal conditional analysis, we conditioned on the lead exome variant by including it as a 1296 
covariate in the cis-eQTL detection and reporting the p-value of the eSNP and vice versa. We considered 1297 
the signals to be coincident if both the lead exome variant and the eSNP were no longer significant after 1298 
conditioning on the other and the variants were in high pairwise LD (r2 > 0.80). 1299 
For loci that also harbored reported GWAS variants, we performed reciprocal conditional 1300 
analysis between the GWAS lead variant and the lead eSNP. For loci with more than one reported GWAS 1301 
variant, the GWAS lead variant with the strongest LD r2 with the lead eSNP was reported. 1302 
Penetrance analysis 1303 
Phenotype and genotype data from the UK Biobank (UKBB) were used for the penetrance 1304 
analysis. Three of 16 rare and low frequency variants (MAF ≤ 1%) detected in the final Stage 1 plus 2 1305 
meta-analysis were available in the UKBB and had relatively larger effect sizes (>0.90). The phenotype 1306 
data for these three variants were stratified with respect to waist-to-hip ratio (WHR) using the World 1307 
Health Organization (WHO) guidelines. These guidelines consider women and men with WHR greater 1308 
than 0.85 and 0.90 as obese, respectively. Genotype and allele counts were obtained for the available 1309 
variants and these were used to calculate the number of carriers of the minor allele. The number of 1310 
carriers for women, men and all combined was then compared between two strata (obese vs. non-1311 
obese) using a χ2 test. The significance threshold was determined by using a Bonferroni correction for 1312 
the number of tests performed (0.05/9=5.5x10-3)).  1313 
DATA AVAILABILITY  1314 
Summary statistics of all analyses are available at https://www.broadinstitute.org/collaboration/giant/. 1315 
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BOXES 1317 
Box 1. Genes of biological interest harboring WHR-associated variants 
PLXND1- (3:129284818, rs2625973, known locus) The major allele of a common non-synonymous 
variant in Plexin D1 (L1412V, MAF=26.7%) is associated with increased WHRadjBMI (β (SE)= 0.0156 
(0.0024), P-value=9.16E-11). PLXND1 is a semaphorin class 3 and 4 receptor gene, and therefore, is 
involved in cell to cell signaling and regulation of growth in development for a number of different cell 
and tissue types, including those in the cardiovascular system, skeleton, kidneys, and the central 
nervous system82-86. Mutations in this gene are associated with Moebius syndrome87-90, and persistent 
truncus arteriosus84,91. PLXND1 is involved in angiogenesis as part of the SEMA and VEGF signalling 
pathways92-95. PLXND1 was implicated in the development of T2D through its interaction with SEMA3E in 
mice. SEMA3E and PLXND1 are upregulated in adipose tissue in response to diet-induced obesity, 
creating a cascade of adipose inflammation, insulin resistance, and diabetes mellitus86. PLXND1 is highly 
expressed in adipose (both subcutaneous and visceral) (GTeX). PLXND1 is highly intolerant of mutations 
and therefore highly conserved (Supplementary Table 12). Last, our lead variant is predicted as 
damaging or possibly damaging for all algorithms examined (SIFT, Polyphen2/HDIV, Polyphen2/HVAR, 
LRT, MutationTaster).  
 
ACVR1C– (2:158412701, rs55920843, novel locus) The major allele of a low frequency non-synonymous 
variant in activin A receptor type 1C (rs55920843, N150H, MAF=1.1%) is associated with increased 
WHRadjBMI (β (SE)= 0.0652 (0.0105), P-value= 4.81E-10). ACVR1C, also called Activin receptor-like 
kinase 7 (ALK7), is a type I receptor for TGFB (Transforming Growth Factor, Beta-1), and is integral for 
the activation of SMAD transcription factors; therefore, ACVR1C plays an important role in cellular 
growth and differentiation49-53, including adipocytes53. Mouse Acvr1c decreases secretion of insulin and 
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is involved in lipid storage96. Mouse Acvr1c decreases secretion of insulin and is involved in lipid 
storage54,57,58. ACVR1C exhibits the highest expression in adipose tissue, but is also highly expressed in 
the brain54-56. Expression is associated with body fat, carbohydrate metabolism and lipids in both obese 
and lean individuals55. ACVR1C is moderately tolerant of variants (EXaC Constraint Scores: synonymous= 
-0.86, nonsynonymous = 1.25, LoF = 0.04). Last, our lead variant is predicted as damaging for two of five 
algorithms examined (LRT and MutationTaster). 
 
FGFR2– (10:123279643, rs138315382, novel locus) The minor allele of a rare synonymous variant in 
Fibroblast Growth Factor Receptor 2 (rs138315382, MAF=0.09%) is associated with increased 
WHRadjBMI (β (SE) = 0.258 (0.049), P-value= 1.38E-07). The extracellular portion of the FGFR2 protein 
binds with fibroblast growth factors, influencing mitogenesis and differentiation. Mutations in this gene 
have been associated with many rare monogenic disorders, including skeletal deformities, 
craniosynostosis, eye abnormalities, and LADD syndrome, as well as several cancers including breast, 
lung, and gastric cancer. Methylation of FGFR2 is associated with high birth weight percentile97. FGFR2 is 
tolerant of synonymous mutations, but highly intolerant of missense and loss-of-function mutations 
(ExAC Constraint scores: synonymous=-0.9, missense=2.74, LoF=1.0) (Supplementary Table 13). Last, 
this variant is not predicted to be damaging based on any of the 5 algorithms tested. 
 
ANGPTL4 – (19:8429323, rs116843064, novel locus) The major allele of a nonsynonymous low frequency 
variant in Angiopoietin Like 4 (rs116843064, E40K, EAF=98.1%) is associated with increased WHRadjBMI 
(β (SE) = 0.064 (0.011) P-value= 1.20E-09). ANGPTL4 encodes a glycosylated, secreted protein containing 
a C-terminal fibrinogen domain. The encoded protein is induced by peroxisome proliferation activators 
and functions as a serum hormone that regulates glucose homeostasis, triglyceride metabolism98,99, and 
insulin sensitivity100. Angptl4-deficient mice have hypotriglyceridemia and increased lipoprotein lipase 
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(LPL) activity, while transgenic mice overexpressing Angplt4 in the liver have higher plasma triglyceride 
levels and decreased LPL activity101. The major allele of rs116843064 has been previously associated 
with increased risk of coronary heart disease and increased TG48. ANGPTL4 is moderately tolerant of 
mutations (ExAC constraint scores synonymous=1.18, missense=0.21, LoF=0.0). Last, our lead variant is 
predicted damaging for four of five algorithms (SIFT, Polyphen 2/HDIV, Polyphen2/HVAR, and 
MutationTaster). 
 
RREB1- (6:7211818, rs1334576, novel association signal) The major allele of a common non-synonymous 
variant in the Ras responsive element binding protein 1 (rs1334576, G195R, EAF=56%) is associated with 
increased WHRadjBMI (β (SE)=0.017 (0.002), P-value=3.9x10-15). This variant is independent of the 
previously reported GWAS signal in the RREB1 region (rs1294410; 6:673875210). The protein encoded by 
this gene is a zinc finger transcription factor that binds to RAS-responsive elements (RREs) of gene 
promoters. It has been shown that the calcitonin gene promoter contains an RRE and that the encoded 
protein binds there and increases expression of calcitonin, which may be involved in Ras/Raf-mediated 
cell differentiation102-104. The ras responsive transcription factor RREB1 is a candidate gene for type 2 
diabetes associated end-stage kidney disease103. This variant is highly intolerant to loss of function (ExAC 
constraint score LoF = 1). 
 
DAGLB- (7:6449496, rs2303361, novel locus) The minor allele of a common non-synonymous variant 
(rs2303361,Q664R, MAF=22%) in DAGLB (Diacylglycerol lipase beta) is associated with increased 
WHRadjBMI (β (SE)= 0.0136 (0.0025), P-value=6.24x10-8). DAGLB is a diacylglycerol (DAG) lipase that 
catalyzes the hydrolysis of DAG to 2-arachidonoyl-glycerol, the most abundant endocannabinoid in 
tissues. In the brain, DAGL activity is required for axonal growth during development and for retrograde 
synaptic signaling at mature synapses (2-AG)105. The DAGLB rs702485 (7:6449272, r2= 0.306 and D’=1 
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with rs2303361) variant has been previously associated with high-density lipoprotein cholesterol (HDL) 
previously. Pathway analysis indicate a role in the triglyceride lipase activity pathway 106. DAGLB is 
tolerant of synonymous mutations, but intolerant of missense and loss of function mutations (ExAC 
Constraint scores: synonymous=-0.76, missense=1.07, LoF=0.94). Last, this variant is not predicted to be 
damaging by any of the algorithms tested.  
 
MLXIPL (7:73012042, rs35332062 and 7:73020337, rs3812316, known locus) The major alleles of two 
common non-synonymous variants (A358V, MAF=12%; Q241H, MAF=12%) in MLXIPL (MLX interacting 
protein like) are associated with increased WHRadjBMI (β (SE)= 0.02 (0.0033), P-value=1.78x10-9; β (SE)= 
0.0213 (0.0034), P-value=1.98x10-10). These variants are in strong linkage disequilibrium (r2=1.00, 
D’=1.00, 1000 Genomes CEU). This gene encodes a basic helix-loop-helix leucine zipper transcription 
factor of the Myc/Max/Mad superfamily. This protein forms a heterodimeric complex and binds and 
activates carbohydrate response element (ChoRE) motifs in the promoters of triglyceride synthesis 
genes in a glucose-dependent manner59,60. This gene is possibly involved in the growth hormone 
signaling pathway and lipid metabolism. The WHRadjBMI-associated variant in this gene has been 
associated with the levels, risk of non-alcoholic fatty liver disease and coronary artery disease . This gene 
possibly involved in the growth hormone signaling pathway and lipid metabolism. The WHRadjBMI-
associated variant rs3812316 in this gene has been associated with the levels, risk of non-alcoholic fatty 
liver disease and coronary artery disease59,107,108. Furthermore, Williams-Beuren syndrome (an 
autosomal dominant disorder characterized by short stature, abnormal weight gain, various 
cardiovascular defects, and mental retardation) is caused by a deletion of about 26 genes from the long 
arm of chromosome 7 including MLXIPL. MLXIPL is generally intolerant to variation, and therefore 
conserved (ExAC Constraint scores: synonymous = 0.48, missense=1.16, LoF=0.68). Last, both variants 
reported here are predicted as possible or probably damaging by one of the algorithms tested 
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(PolyPhen).  
 
RAPGEF3 (12:48143315, rs145878042, novel locus) The major allele of a low frequency non-synonymous 
variant in Rap Guanine-Nucleotide-Exchange Factor (GEF) 3 (rs145878042, L300P, MAF=1.1%) is 
associated with increased WHRadjBMI (β (SE)=0.085 (0.010), P-value = 7.15E-17). RAPGEF3 is an 
intracellular cAMP sensor, also known as Epac (the Exchange Protein directly Activated by Cyclic AMP). 
Among its many known functions, RAPGEF3 regulates the ATP sensitivity of the KATP channel involved in 
insulin secretion109, may be important in regulating adipocyte differentiation110-112, and plays an 
important role in regulating adiposity and energy balance113, and plays an important role in regulating 
adiposity and energy balance113. RAPGEF3 is tolerant of mutations (ExAC Constraint Scores: synonymous 
= -0.47, nonsynonymous = 0.32, LoF = 0). Last, our lead variant is predicted as damaging or possibly 
damaging for all five algorithms examined herein (SIFT, Polyphen2/HDIV, Polyphen2/HVAR, LRT, 
MutationTaster).  
 
TBX15 (1:119427467, rs61730011, known locus) The major allele of a low frequency non-synonymous 
variant in T-box 15 (rs61730011, M460R, MAF=4.3%) is associated with increased WHRadjBMI 
(β(SE)=0.041(0.005)). T-box 15 (TBX15) is a developmental transcription factor expressed in adipose 
tissue, but with higher expression in visceral adipose tissue than in subcutaneous adipose tissue, and 
strongly downregulated in overweight and obese individuals114. TBX15 negatively controls depot-specific 
adipocyte differentiation and function115 and regulates glycolytic myofiber identity and muscle 
metabolism116. TBX15 is moderately intolerant of mutations and therefore conserved (ExAC Constraint 
Scores: synonymous = 0.42, nonsynonymous = 0.65, LoF = 0.88). Last, our lead variant is predicted as 
damaging or possibly damaging for four algorithms (Polyphen2/HDIV, Polyphen2/HVAR, LRT, 
MutationTaster). 
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FIGURES 1580 
Figure 1. Summary of meta-analysis study design and workflow. Abbreviations: 1581 
EUR- European, AFR- African, SAS- South Asian, EAS- East Asian, and HIS- Hispanic/Latino ancestry. 1582 
Figure 2. Minor allele frequency compared to estimated effect. This scatter plot displays the relationship 1583 
between minor allele frequency (MAF) and the estimated effect (β) for each significant coding variant in 1584 
our meta-analyses. All novel WHRadjBMI variants are highlighted in orange, and variants identified only 1585 
in models that assume recessive inheritance are denoted by diamonds and only in sex-specific analyses 1586 
by triangles. Eighty percent power was calculated based on the total sample size in the Stage 1+2 meta-1587 
analysis and P=2x10-7. Estimated effects are shown in original units (cm/cm) calculated by using effect 1588 
sizes in standard deviation (SD) units times SD of WHR in the ARIC study (sexes combined=0.067, 1589 
men=0.052, women=0.080).  1590 
Figure 3. Regional association plots for known loci with novel coding signals. Point color reflects r2 1591 
calculated from the ARIC dataset. In a) there are two independent variants in RSPO3 and KIAA0408, as 1592 
shown by conditional analysis. In b) we have a variant in RREB1 that is independent of the GWAS variant 1593 
rs1294421. 1594 
Figure 4. Heat maps showing DEPICT gene set enrichment results. For any given square, the color 1595 
indicates how strongly the corresponding gene (shown on the x-axis) is predicted to belong to the 1596 
reconstituted gene set (y-axis). This value is based on the gene’s z-score for gene set inclusion in 1597 
DEPICT’s reconstituted gene sets, where red indicates a higher and blue a lower z-score. To visually 1598 
reduce redundancy and increase clarity, we chose one representative "meta-gene set" for each group of 1599 
highly correlated gene sets based on affinity propagation clustering (Online Methods, Supplementary 1600 
Information). Heatmap intensity and DEPICT P-values (see P-values in Supplementary Data 4-5) 1601 
correspond to the most significantly enriched gene set within the meta-gene set. Annotations for the 1602 
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genes indicate (1) the minor allele frequency of the significant ExomeChip (EC) variant (shades of blue; if 1603 
multiple variants, the lowest-frequency variant was kept), (2) whether the variant’s P-value reached 1604 
array-wide significance (<2x10-7) or suggestive significance (<5x10-4) (shades of purple), (3) whether the 1605 
variant was novel, overlapping “relaxed” GWAS signals from Shungin et al.10 (GWAS P<5x10-4), or 1606 
overlapping “stringent” GWAS signals (GWAS P<5x10-8) (shades of pink), and (4) whether the gene was 1607 
included in the gene set enrichment analysis or excluded by filters (shades of brown/orange) (Online 1608 
Methods and Supplementary Information). Annotations for the gene sets indicate if the meta-gene set 1609 
was found significant (shades of green; FDR <0.01, <0.05, or not significant) in the DEPICT analysis of 1610 
GWAS results from Shungin et al. 1611 
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TABLES 1614 
Table 1. Association results for Combined Sexes. Association results based on an additive or recessive model for coding variants that met array-wide significance (P<2x10-07) in the sex-1615 
combined meta-analyses. 1616 
 1617 
Locus (+/-
1Mb of a 
given 
variant) 
Chr:Position 
(GRCh37)b 
rsID 
Effect  
Allele 
Other 
Allele 
Genec 
Amino Acid 
Changec 
If locus is known, 
nearby (< 1 MB) 
published 
variant(s) d 
N 
Effect Allele 
Frequency 
Effect sizee 
(SD/allele) 
SE P-value 
P-value for Sex-
heterogeneityf 
Variants in Novel Loci 
All Ancestry Additive model Sex-combined analyses 
1 2:158412701 rs55920843 T G ACVR1C N150H - 455,526 0.989 0.065 0.011 4.8E-10 1.7E-07 
2 3:50597092 rs1034405 G A C3orf18 A162V - 455,424 0.135 0.016 0.003 1.9E-07 8.8E-01 
3 4:120528327 rs3733526 G A PDE5A A41V - 461,521 0.187 0.015 0.003 2.6E-08 5.2E-03 
4 6:26108117 rs146860658 T C HIST1H1T A69T - 217,995 0.001 0.229 0.042 4.3E-08 6.3E-01 
5 7:6449496 rs2303361 C T DAGLB Q664R - 475,748 0.221 0.014 0.003 6.2E-08 3.4E-03 
6 10:123279643 rs138315382 T C FGFR2 synonymous - 236,962 0.001 0.258 0.049 1.4E-07 1.1E-01 
7 11:65403651 rs7114037 C A PCNXL3 H1822Q - 448,861 0.954 0.029 0.005 1.8E-08 4.4E-01 
8 12:48143315 rs145878042 A G RAPGEF3 L300P - 470,513 0.990 0.085 0.010 7.2E-17 7.3E-03 
9 12:108618630 rs3764002 C T WSCD2 T266I - 474,637 0.737 0.014 0.002 9.8E-10 5.5E-01 
10 15:42032383 rs17677991 G C MGA P1523A - 469,874 0.345 0.015 0.002 3.5E-11 9.1E-01 
11 
16:4432029 rs3810818 A C VASN E384A - 424,163 0.231 0.016 0.003 2.0E-09 3.3E-01 
16:4445327 rs3747579 C T CORO7 R193Q - 453,078 0.299 0.018 0.002 2.2E-13 4.3E-02 
16:4484396 rs1139653 A T DNAJA3 N75Y - 434,331 0.284 0.015 0.002 4.3E-10 1.4E-01 
  
  2 
12 
19:49232226 rs2287922 A G RASIP1 R601C - 430,272 0.494 0.014 0.002 1.6E-09 3.7E-02 
19:49244220 rs2307019 G A IZUMO1 A333V - 476,147 0.558 0.012 0.002 4.7E-08 3.9E-02 
13 20:42965811 rs144098855 T C R3HDML P5L - 428,768 0.001 0.172 0.032 9.7E-08 1.0E+00 
European Ancestry Additive model Sex-combined analyses   
14 1:173802608 rs35515638 G A DARS2 K196R - 352,646 0.001 0.201 0.038 1.4E-07 6.0E-02 
15 14:58838668 rs1051860 A G ARID4A synonymous - 367,079 0.411 0.013 0.002 2.2E-08 1.3E-01 
16 15:42115747 rs3959569 C G MAPKBP1 R1240H - 253,703 0.349 0.017 0.003 2.0E-08 6.3E-01 
Variants in Previously Identified Loci 
All Ancestry Additive model Sex-combined analyses 
1 
1:119427467 rs61730011 A C 
TBX15 
M566R 
rs2645294, 
rs12731372, 
rs12143789, 
rs1106529 
441,461 0.957 0.041 0.005 2.2E-14 6.7E-01 
1:119469188 rs10494217 T G H156N 472,259 0.174 0.018 0.003 1.4E-10 6.0E-01 
2 1:154987704 rs141845046 C T ZBTB7B P190S rs905938 476,440 0.976 0.037 0.007 3.8E-08 7.9E-07 
3 2:165551201 rs7607980 T C COBLL1 N941D 
rs1128249, 
rs10195252, 
rs12692737, 
rs12692738, 
rs17185198 
389,883 0.879 0.026 0.004 1.6E-13 3.0E-30 
4 2:188343497 rs7586970 T C TFPI N221S rs1569135 452,638 0.697 0.016 0.002 3.0E-12 6.3E-01 
5 
3:52558008 rs13303 T C STAB1 M113T 
rs2276824 
470,111 0.445 0.019 0.002 5.5E-18 6.7E-02 
3:52833805 rs3617 C A ITIH3 Q315K 452,150 0.541 0.015 0.002 1.6E-12 4.0E-01 
6 
3:129137188 rs62266958 C T EFCAB12 R197H 
rs10804591 
476,382 0.936 0.036 0.004 8.3E-17 9.3E-05 
3:129284818 rs2625973 A C PLXND1 L1412V 476,338 0.733 0.016 0.002 9.2E-11 1.6E-05 
7 
4:89625427 rs1804080 G C HERC3 E946Q 
rs9991328 
446,080 0.838 0.021 0.003 1.5E-12 4.1E-06 
4:89668859 rs7657817 C T FAM13A V443I 476,383 0.815 0.016 0.003 5.0E-09 9.6E-05 
8 5:176516631 rs1966265 A G FGFR4 V10I rs6556301 455,246 0.236 0.023 0.003 1.7E-19 2.1E-01 
9 6:7211818 rs1334576g G A RREB1 G195R rs1294410 451,044 0.565 0.017 0.002 3.9E-15 1.5E-01 
10 6:34827085 rs9469913 A T UHRF1BP1 Q984H rs1776897 309,684 0.847 0.021 0.004 1.2E-08 2.7E-01 
  
  3 
11 
6:127476516 rs1892172 A G RSPO3 synonymous rs11961815, 
rs72959041, 
rs1936805 
476,358 0.543 0.031 0.002 2.6E-47 7.7E-09 
6:127767954 rs139745911 g A G KIAA0408 P504S 391,469 0.010 0.103 0.012 6.8E-19 2.0E-04 
12 
7:73012042 rs35332062 G A 
MLXIPL 
A358V 
rs6976930 
451,158 0.880 0.020 0.003 1.8E-09 1.5E-01 
7:73020337 rs3812316 C G Q241H 454,738 0.881 0.021 0.003 2.0E-10 5.8E-02 
13 10:95931087 rs17417407 T G PLCE1 R240L rs10786152 476,475 0.173 0.018 0.003 2.5E-11 5.9E-01 
14 11:64031241 rs35169799 T C PLCB3 S778L rs11231693 476,457 0.061 0.034 0.004 9.1E-15 1.3E-04 
15 
12:123444507 rs58843120 G T ABDB9 F92L 
rs4765219, 
rs863750 
466,498 0.987 0.053 0.009 1.3E-08 3.5E-01 
12:124265687 rs11057353 T C 
DNAH10 
S228P 476,360 0.373 0.018 0.002 2.1E-16 2.7E-08 
12:124330311 rs34934281 C T T1785M 476,395 0.889 0.025 0.003 2.9E-14 3.1E-08 
12:124427306 rs11057401 T A CCDC92 S53C 467,649 0.695 0.029 0.002 7.3E-37 5.5E-11 
16 15:56756285 rs1715919 G T MNS1 Q55P rs8030605 476,274 0.096 0.023 0.004 8.8E-11 2.7E-02 
17 
16:67397580 rs9922085 G C 
LRRC36 
R101P 
rs6499129 
469,474 0.938 0.034 0.005 3.8E-13 5.9E-01 
16:67409180 rs8052655 G A G388S 474,035 0.939 0.034 0.005 5.5E-13 4.0E-01 
18 
19:18285944 rs11554159 A G IFI30  R76Q 
rs12608504 
476,389 0.257 0.015 0.002 3.5E-10 3.1E-03 
19:18304700 rs874628 G A MPV17L2 M72V 476,388 0.271 0.015 0.002 1.2E-10 2.5E-03 
19 
20:33971914 rs4911494 T C UQCC1 R51Q 
rs224333 
451,064 0.602 0.018 0.002 2.5E-16 1.5E-03 
20:34022387 rs224331 A C GDF5 S276A 345,805 0.644 0.017 0.003 1.8E-11 3.2E-03 
All Ancestry Recessive model Sex-combined analyses   
20 17:17425631 rs897453 C T PEMT V58L rs4646404 476,546 0.569 0.025 0.004 4.1E-11 8.2E-01 
European Ancestry Additive model Sex-combined analyses   
6 3:129293256 rs2255703 T C PLXND1 M870V rs10804591 420,520 0.620 0.014 0.002 3.1E-09 1.6E-04 
Abbreviations: GRCh37=human genome assembly build            37;rsID=based on dbSNP; VEP=Ensembl Variant Effect Predictor toolset; 1618 
GTEx=Genotype-Tissue Expression project;SD=standard deviation; SE=standard error;N=sample size  1619 
a Coding variants refer to variants located in the exons and splicing junction regions.          1620 
b Variant positions are reported according to Human assembly build 37 and their alleles are coded based on the positive strand.  1621 
c The gene the variant falls in and amino acid change from the most abundant coding transcript is shown (protein annotation is based on VEP toolset and transcript abundance from GTEx database).  1622 
d Previously published variants within +/-1Mb are from Shungin et al.10, except for rs6976930 and rs10786152 from Graff et al.14 and rs6499129 from Ng. et al 16. 1623 
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e Effect size is based on standard deviation (SD) per effect allele  1624 
f P-value for sex heterogeneity, testing for difference between women-specific and men-specific beta estimates and standard errors, was calculated using  EasyStrata: Winkler, T.W. et al. EasyStrata: evaluation and visualization of 1625 
stratified genome-wide association meta-analysis data. Bioinformatics 2015: 31, 259-61.PMID: 25260699. Bolded P-values met significance threshold after bonferonni correction (P-value<7.14E-04; i.e. 0.05/70 variants).  1626 
g rs1334576 in RREB1 is a new signal in a known locus that is independent from the known signal, rs1294410; rs139745911 in KIAA0408 is a new signal in a known locus that is independent from all known signals rs11961815, 1627 
rs72959041, rs1936805, in a known locus (see Supplementary 8A/B).             1628 
1629 
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Table 2. Association results for Sex-stratified analyses. Association results based on an additive or recessive model for coding variants that met array-wide significance (P<2x10-07) in the sex-1630 
specific meta-analyses and reach bonferonni corrected P-value for sex hetergeneity (Psexhet<7.14E-04). 1631 
Locus (+/-
1Mb of a 
given 
variant) 
Chr:Position 
(GRCh37)c 
rsID 
Effect 
Allele 
Other 
Allele 
Gened 
Amino Acid 
Changed 
Identified in 
sex-
combined 
analysese 
If locus is 
known, nearby 
(< 1 MB) 
published 
variant(s) f 
Psexhet 
Men Women 
N EAF 
Effecth 
(SD/ allele) 
SE P N EAF 
Effecth 
(SD/ 
allele) 
SE P 
Variants in Novel Loci 
All Ancestry Additive model Men only analyses 
1 13:96665697 rs148108950 A G UGGT2 P175L No - 1.5E-06 203,009 0.006 0.130 0.024 6.1E-08 221,390 0.004 -0.044 0.027 1.1E-01 
2 14:23312594 rs1042704 A G MMP14 D273N No - 2.6E-04 226,646 0.202 0.021 0.004 2.6E-08 250,018 0.197 0.002 0.004 6.1E-01 
All Ancestry Additive model Women only analyses 
3 1:205130413 rs3851294 G A DSTYK C641R No - 9.8E-08 225,803 0.914 -0.005 0.005 3.4E-01 249,471 0.912 0.034 0.005 4.5E-11 
4 2:158412701 rs55920843 T G ACVR1C N150H Yes - 1.7E-07 210,071 0.989 0.006 0.015 7.2E-01 245,808 0.989 0.113 0.014 1.7E-15 
5 19:8429323 rs116843064 G A ANGPTL4 E40K No - 1.3E-07 203,098 0.981 -0.017 0.011 1.4E-01 243,351 0.981 0.064 0.011 1.2E-09 
Variants in Previously Identified Loci 
All Ancestry Additive model Women only analyses 
1 1:154987704 rs141845046 C T ZBTB7B P190S Yes rs905938 7.9E-07 226,709 0.975 0.004 0.010 6.9E-01 250,084 0.977 0.070 0.010 2.3E-13 
2 2:165551201 rs7607980 T C COBLL1 N941D Yes 
rs1128249, 
rs10195252, 
rs12692737, 
rs12692738, 
rs17185198 
3.0E-30 173,600 0.880 -0.018 0.005 5.8E-04 216,636 0.878 0.062 0.005 6.7E-39 
3 
3:129137188 rs62266958 C T EFCAB12 R197H Yes 
rs10804591 
9.3E-05 226,690 0.937 0.018 0.006 3.1E-03 250,045 0.936 0.051 0.006 8.1E-18 
3:129284818 rs2625973 A C 
 PLXND1 
L1412V Yes 1.6E-05 226,650 0.736 0.005 0.003 1.9E-01 250,023 0.730 0.025 0.003 8.2E-14 
3:129293256 rs2255703 T C M870V Yes 5.0E-04 226,681 0.609 0.003 0.003 3.1E-01 250,069 0.602 0.018 0.003 1.9E-09 
4 
4:89625427 rs1804080 G C HERC3 E946Q Yes 
rs9991328 
4.1E-06 222,556 0.839 0.008 0.004 6.6E-02 223,877 0.837 0.034 0.004 2.1E-16 
4:89668859 rs7657817 C T FAM13A V443I Yes 9.6E-05 226,680 0.816 0.006 0.004 1.5E-01 242,970 0.815 0.026 0.004 5.9E-12 
  
  6 
5 
6:127476516 rs1892172 A G RSPO3 synonymous Yes rs11961815, 
rs72959041, 
rs1936805 
7.7E-09 226,677 0.541 0.018 0.003 5.6E-10 250,034 0.545 0.042 0.003 3.4E-48 
6:127767954 rs139745911i A G KIAA0408 P504S Yes 2.0E-04 188,079 0.010 0.057 0.017 6.8E-04 205,203 0.010 0.143 0.016 5.9E-19 
6 11:64031241 rs35169799 T C PLCB3 S778L Yes rs11231693 1.3E-04 226,713 0.061 0.016 0.006 9.6E-03 250,097 0.061 0.049 0.006 6.7E-16 
7 
12:12426568
7 
rs11057353 T C 
DNAH10 
S228P Yes 
rs4765219, 
rs863750 
2.7E-08 226,659 0.370 0.005 0.003 8.3E-02 250,054 0.376 0.029 0.003 3.1E-22 
12:12433031
1 
rs34934281 C T T1785M Yes 3.1E-08 226,682 0.891 0.006 0.005 1.9E-01 250,066 0.887 0.043 0.005 1.4E-20 
12:12442730
6 
rs11057401 T A CCDC92 S53C Yes 5.5E-11 223,324 0.701 0.013 0.003 4.3E-05 244,678 0.689 0.043 0.003 1.0E-41 
Abbreviations: GRCh37=human genome assembly build 37;rsID=based on dbSNP; VEP=Ensembl Variant Effect Predictor toolset; GTEx=Genotype-Tissue Expression project;SD=standard deviation; SE=standard error;N=sample size 
a Coding variants           refer to variants located in the exons and splicing junction regions.  
b Bonferonni corrected Pvalue for the number of SNPs tested for sex-heterogeneity is <7.14E-04 i.e. 0.05/70 variants. 
c Variant positions are reported according to Human assembly build 37 and their alleles are coded based on the positive strand.  
d The gene the variant falls in and amino acid change from the most abundant coding transcript is shown (protein annotation is based on VEP toolset and transcript abundance from GTEx database). 
e Variant was also identified as array-wide significant in the sex-combined analyses.             
f Previously published variants within +/-1Mb are from Shungin D et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 2015; 518, 187–196 doi:10.1038/nature14132 (PMID 25673412). 
g P-value for sex heterogeneity, testing for difference between women-specific and men-specific beta estimates and standard errors, was calculated using EasyStrata: Winkler, T.W. et al. EasyStrata: evaluation and visualization of stratified genome-wide association meta-analysis data. 
Bioinformatics 2015: 31, 259-61. PMID: 25260699. 
h Effect size is based on standard deviation (SD) per effect allele 
i rs139745911 in KIAA0408 is a new signal in a known locus that is independent from all known signals rs11961815, rs72959041, rs1936805, in a known locus (see Supplementary 8A/B).  
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